Benzinga | Nov 5, 2021 09:42AM EDT

Equillium Highlights Presentation Of Interim Safety Data From First Cohort Of Asthma Patients In Phase 1b EQUIP Study At American College Of Allergy, Asthma, Immunology Meeting Friday At 6:45 p.m. EDT

Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today reported interim data from the first cohort in its randomized, placebo-controlled Phase 1b EQUIP study for itolizumab in patients with moderate to severe uncontrolled asthma. These data, which summarize early safety and clinical activity, are part of a poster presentation available to registered attendees of the hybrid, in-person/virtual, American College of Allergy, Asthma & Immunology meeting being held in New Orleans. A presentation of the poster will be given by Reynold A. Panettieri, Jr., M.D., Rutgers Institute for Translational Medicine and Science.

Presentation ID: P071

Category: Asthma, Other Lower Airway Disorders

Abstract Title: EQUIP Interim Results: A Phase 1b Study Evaluating Itolizumab in Subjects with Moderate-to-Severe Uncontrolled Asthma

In-Person Author Presentation Scheduled for: Monitor 9

Presentation: Friday, November 5, 6:45 PM ET

"Our clinical data continue to support the versatility and therapeutic utility of itolizumab in a number of autoimmune and inflammatory disorders," said Dolca Thomas, M.D., executive vice president of research and development and chief medical officer of Equillium. "These data support the tolerability, and the clinical potential of dosing itolizumab subcutaneously in patients with moderate-to-severe asthma. We look forward to reporting topline data from the EQUIP study later this year."

The EQUIP trial is evaluating ascending doses of itolizumab compared to placebo administered subcutaneously every two weeks (SC Q2W) up to Day 57. The poster highlighted blinded data from nine patients in Cohort 1 (itolizumab 0.8 mg/kg or placebo) with a baseline mean ACQ-6 (asthma control questionnaire) in the cohort of 2.5, which decreased to 1.5 at Day 29, and maintained this level 30 days after the last dose of itolizumab at Day 85. Mean FEV-1 (forced expiratory volume - a measure of airway obstruction) was 2.1 on Day 1, which increased to 2.4 at Day 29 and maintained at Day 85. Interim pharmacodynamic findings indicated a reduction of cell surface expression of CD6 compared to placebo. Itolizumab was well tolerated with most adverse events characterized as mild to moderate in severity, consisting primarily of injection site reactions and transient lymphopenia events consistent with prior experience of itolizumab administration.

To view the poster presentation, visit the Publications & Presentations page of Equillium's website: https://www.equilliumbio.com/technology/publications-presentations/default.aspx.